JP2018515510A - ｃＭＬＣＫ遺伝子導入 - Google Patents

ｃＭＬＣＫ遺伝子導入 Download PDF

Info

Publication number
JP2018515510A
JP2018515510A JP2017558467A JP2017558467A JP2018515510A JP 2018515510 A JP2018515510 A JP 2018515510A JP 2017558467 A JP2017558467 A JP 2017558467A JP 2017558467 A JP2017558467 A JP 2017558467A JP 2018515510 A JP2018515510 A JP 2018515510A
Authority
JP
Japan
Prior art keywords
cmlck
subject
seq
polynucleotide
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017558467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515510A5 (https=
Inventor
ズホウ ミングドング
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．, ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2018515510A publication Critical patent/JP2018515510A/ja
Publication of JP2018515510A5 publication Critical patent/JP2018515510A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11018—Myosin-light-chain kinase (2.7.11.18)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
JP2017558467A 2015-05-08 2016-06-14 ｃＭＬＣＫ遺伝子導入 Pending JP2018515510A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNCN201510232415.6 2015-05-08
CN201510232415.6A CN106177992A (zh) 2015-05-08 2015-05-08 cMLCK基因导入
PCT/CN2016/085699 WO2016180377A1 (zh) 2015-05-08 2016-06-14 cMLCK基因导入

Publications (2)

Publication Number Publication Date
JP2018515510A true JP2018515510A (ja) 2018-06-14
JP2018515510A5 JP2018515510A5 (https=) 2019-07-11

Family

ID=57247711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558467A Pending JP2018515510A (ja) 2015-05-08 2016-06-14 ｃＭＬＣＫ遺伝子導入

Country Status (10)

Country Link
US (1) US20180133291A1 (https=)
EP (1) EP3295959A4 (https=)
JP (1) JP2018515510A (https=)
KR (1) KR20190008511A (https=)
CN (3) CN106177992A (https=)
AU (1) AU2016260473A1 (https=)
BR (1) BR112017024065A2 (https=)
CA (1) CA2985396A1 (https=)
RU (1) RU2017142779A (https=)
WO (1) WO2016180377A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
CN106177992A (zh) * 2015-05-08 2016-12-07 上海泽生科技开发有限公司 cMLCK基因导入
CN115838437A (zh) * 2022-11-04 2023-03-24 广州达安基因股份有限公司 人NT-proBNP融合蛋白及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126860A1 (en) * 2000-09-12 2004-07-01 Epstein Neal D Optimized cardiac contraction through differential phosphorylation of myosin
JP2009242388A (ja) * 2008-03-14 2009-10-22 National Cardiovascular Center 心臓特異的キナーゼの心不全診断および治療への応用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580515B2 (en) * 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN102416184A (zh) * 2011-12-08 2012-04-18 哈尔滨医科大学 microRNA-1的反义锁核苷酸序列在制备预防或治疗心肌梗死后心衰药物中的应用
CN106177992A (zh) * 2015-05-08 2016-12-07 上海泽生科技开发有限公司 cMLCK基因导入

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126860A1 (en) * 2000-09-12 2004-07-01 Epstein Neal D Optimized cardiac contraction through differential phosphorylation of myosin
JP2009242388A (ja) * 2008-03-14 2009-10-22 National Cardiovascular Center 心臓特異的キナーゼの心不全診断および治療への応用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARDIOVASCULAR RESEARCH, 2010, VOL.88, PP.334-343, JPN6020017635, ISSN: 0004415000 *

Also Published As

Publication number Publication date
US20180133291A1 (en) 2018-05-17
RU2017142779A3 (https=) 2019-12-03
EP3295959A1 (en) 2018-03-21
KR20190008511A (ko) 2019-01-24
BR112017024065A2 (pt) 2018-08-07
EP3295959A4 (en) 2019-01-02
CN106177992A (zh) 2016-12-07
RU2017142779A (ru) 2019-06-10
CN111388682A (zh) 2020-07-10
CA2985396A1 (en) 2016-11-17
CN107735109A (zh) 2018-02-23
WO2016180377A1 (zh) 2016-11-17
AU2016260473A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AU2007221470B2 (en) Phosphatase inhibitor Protein-1 as a regulator of cardiac function
AU2004204815B2 (en) Method for in vivo regulation of cardiac muscle contractility
JP2022520232A (ja) ダノン病の治療のための遺伝子療法ベクター
JP2015503924A (ja) 遺伝子導入のための方法及び組成物
JP2018515510A (ja) ｃＭＬＣＫ遺伝子導入
AU2018297274B2 (en) Treatment of heart disease by inhibition of the action of muscle A-kinase anchoring protein (mAKAP)
US20250057982A1 (en) Proteins with cardioprotective activity
JP2002515065A (ja) 脈管形成トランスジーンのインビボ送達により心不全および心室再構成を処置するための技術および組成物
JP2002514908A (ja) うっ血性心不全のための遺伝子治療
WO2017029206A1 (en) Use of k2p potassium channel for altering the electrophysiology of the heart
KR20230035584A (ko) Dwarf 개방 판독 프레임을 위한 아데노-관련 바이러스 벡터
EP2044199B1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors comprising serca2a for gene therapy
EP3227441B1 (en) Camkk1 as a novel regenerative therapeutic
JP2022507693A (ja) 心不全の治療及び予防における使用のためのリラキシン受容体１
US20230250450A1 (en) NRF2 Activator for Use in Treating Dilated Cardiomyopathies
Sasipong Targeted overexpression of relaxin receptor 1 (RXFP1) with chronic administration of relaxin as a novel inotropic approach for heart failure treatment
CA2293733A1 (en) Mycardium-and skeletal muscle-specific nucleic acid, its preparation and use
WO2015153357A1 (en) Compositions and methods for improving cardiac function
Moilanen Identification of novel drug targets for the treatment of heart failure
HK1129392A (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210105